Infectious Diseases Virtual Partnering
2020-12-02 - 2020-12-04 | VIRTUAL EVENT
Infectious diseases have always impacted human history, but in the past 50 years we have managed to control or eliminate some infectious diseases through improved hygiene, vaccination, antimicrobials, advances in medicine and public health policies. However, the current pandemic is a reminder that we need to continue to pursue our efforts to control these pathogens, especially with intercontinental travel and increased mobility of people and animals.
To manage infectious diseases, we use tools such as vaccines, antibiotics, antivirals, diagnostic tools and biomarkers. But today there are many infectious diseases for which we do not have satisfactory preventive tools or treatment options, such as SARS-CoV-2, Zika virus, Ebola virus, multidrug resistant bacteria, HIV, Malaria. To develop these future tools, collaboration is essential, either for sourcing assets in the vaccine, antiviral or antibiotic space, or for finding research tools to help in screening, in-vivo modelling, clinical trials and diagnostics and biomarkers.
It is in this context that we are organising the Infectious Diseases Virtual Partnering event, focusing on diseases caused by organisms such as bacteria, viruses, fungi, or parasites. With current travel restrictions, this virtual event will help you to find the right business partner to pursue your objectives. This event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Evidence to Action Webinar: Advancing the Antimicrobial Resistance agenda during a pandemic
2020-12-03 03:00 - 04:30 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
How can efforts to implement Antimicrobial Resistance National Action Plans still progress despite the COVID-19 pandemic?
There is no doubt COVID-19 currently represents the most obvious and urgent issue for global health security and the world is rightfully focused on tackling this pandemic. However, the challenges posed by COVID-19 are only a foretaste of what antimicrobial resistance (AMR) can mean to the world without appropriate interventions. AMR, the silent pandemic, can impact many of the global health achievements of past decades and jeopardize efforts to deliver on many of the Sustainable Development Goals.
This webinar provides an opportunity to gain insights into current efforts to continuously move forward the agenda of combatting AMR amidst the COVID-19 pandemic. Key experts and opinion leaders will share their strategic reflections and insights focusing on what evidence and data are currently available and how best to leverage them into action to tackle AMR, especially in low- and middle-income countries.
This event is co-hosted by the International Vaccine Institute (IVI), the International Centre for Antimicrobial Resistance Solutions (ICARS) and the Embassy of Denmark in Korea. Speakers from IVI, ICARS, WHO and the UK will lead the panel discussion. Please join the conversation and ask questions to our panel.
To learn more, click here.
To register, click here.
Please note that registration is required, and a link to webinar will be shared in advance to registered attendees
December 3, 2020
9:00-10:30 AM (CET); 5:00-6:30 PM (KST); 3:00-4:30 AM (EST)

Milken Institute Future of Health Summit
2020-12-07 - 2020-12-10 | Webinar
The Milken Institute Future of Health Summit convenes the best minds in the world to confront the most significant health challenges by matching human, financial, scientific, and educational resources with innovative and impactful ideas. The Summit will focus on the converging crises of public health, economic insecurity, and social injustice. COVID-19 has exposed weaknesses across our health systems, particularly in the treatment of our most vulnerable communities, where access to affordable and quality health care has never been more vital.
Participants include Kevin Outterson, Executive Director of CARB-X, who will be moderating a session entitled “Are Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives” on Tuesday, December 8th from 12:00pm – 1:00pm EST.
Are Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives: Antibiotic treatment in COVID-19 patients is driving antimicrobial resistance (AMR) as secondary infections emerge. While large pharmaceutical companies have retreated from antibiotic development, smaller enterprises have compensated with innovative therapies to ensure an arsenal of anti-infective drugs. But numerous recent bankruptcies show that times are tough even for companies with newly approved antibiotics. Several large pharmaceutical companies recently joined in launching the billion-dollar Antimicrobial Action Fund for antibiotic development. This welcome investment buys time to right the market, but it is clear that a pull incentive is needed to drive the market. What are the lessons to learn from the UK NHS NICE subscription-model pilot? Is a pull incentive enough to attract private investment to antimicrobials? How can we develop a sustainable market for antibiotics so that drug-resistant infections do not become the next pandemic?
Speakers Include:

Michael Boyle
President and CEO, Cystic Fibrosis Foundation
Nick Crabb
Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE)
Sally Davies
UK Special Envoy on Antimicrobial Resistance, UK Government
Odysseas Kostas
Partner and Senior Managing Director, Sarissa Capital

To learn more, click here.
To view the program, click here.

2020 ASM Conference on Next-Generation Sequencing
2020-12-07 - 2020-12-11 | VIRTUAL EVENT
Join us at the virtual 2020 ASM Conference on Next-Generation Sequencing, taking place Dec. 7-11, 2020, and get comprehensive guidance with up-to-date examples in the use of NGS technology for applied results in the traceability and clustering of microbial pathogens associated with food safety, clinical infection, environmental contamination and other potential sources of disease outbreaks. You’ll walk away with access to the available resources and direction you need relating to bioinformatics and epidemiology.
Click here to learn more.
Click here to view the agenda.
Click here to register.

BLUE KNIGHT™ Symposium
2020-12-08 - 2020-12-10 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
CARB-X participants include Erin Duffy, Chief of R&D.
Johnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to form Blue Knight. This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. Find out more about BARDA and its mission at www.PHE.gov/BARDA.
In seeking to combat emerging infectious diseases and other 21st century health threats, the path to better prepared, protected, and healthy individuals, families, and communities could rely on unlocking the collective power of the global community. BLUE KNIGHT™ seeks to answer this call.
On December 8-10, Johnson & Johnson Innovation – JLABS and BARDA will virtually convene the emerging Blue Knight community of thought leaders, innovators and entrepreneurs for a three-day symposium, including interactive sessions focused on key areas of interest in infectious disease, public health, and company acceleration. Sessions will explore high priority areas of interest for scientific and technological innovation aimed for improving our preparedness and response to emerging health security threats.
To learn more, click here.
To register, click here.

National Academy of Science
2021-01-05 | VIRTUAL EVENT
The National Academy of Sciences (NAS) is a private, nonprofit organization of the country’s leading researchers. The NAS recognizes and promotes outstanding science through election to membership; publication in its journal, PNAS; and its awards, programs, and special activities. Through the National Academies of Sciences, Engineering, and Medicine, the NAS provides objective, science-based advice on critical issues affecting the nation.
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more.

Live Webinar: GARDP/REVIVE – Manipulating the host response to treat infections
2021-01-14 11:00 - 12:30 (America/New_York) | WEBINAR, Webinar, Webinar, United States
Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock):

Host defence peptides (HDP; often termed antimicrobial peptides) stimulate protective immunity while suppressing potentially harmful inflammation. Both of these activities can assist in anti-infective therapy.
HDPs work as immune modulators in animal models against ESKAPE pathogen, MDR TB, fungal, malaria and viral infections, as well as sterile inflammation. They are likely to be employed in adjunctive therapy in combination with antibiotics.
HDPs often have additional value-added activities including action against bacterial biofilms in animal models. This allows them to be utilized to address situations where antibiotics commonly fail.
Alternative host-directed therapies can be defined for recalcitrant infections using stem cell mutagenesis and systems biology approaches.

Regulation and reprogramming of the innate immune system as alternative to antibiotics (Henk P. Haagsman):

Host defence peptides (HDP) are immunomodulatory antimicrobials. – Cathelicidin-derived peptides may serve as paradigms to develop anti-inflammatory anti-infectives.
Cathelicidin-derived peptides may be used prophylactically as immunomodulators and adjuvants in veterinary medicine.
Host-directed therapy may include innate immune training by epigenetic reprogramming. The presentations will be followed by a Q&A session.

Speakers: R.E.W. (Bob) Hancock, University of British Columbia (Canada); Henk P. Haagsman, Utrecht University (Netherlands)
Moderator: Neeloffer Mookherjee, Departments of Internal Medicine and Immunology, University of Manitoba (Canada)
Click here to learn more and register.

Keystone Symposia: Harnessing the Microbiome for Disease Prevention and Therapy
2021-01-18 - 2021-01-20 | VIRTUAL EVENT
Joint meeting with: The Microbiome: From Mother to Child
January 18-20, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET*
Our understanding of the microbiome is advancing rapidly, and continues to productively move through the discovery phase, with numerous correlations being established between specific commensal microbes or microbiota compositions and a wide range of diseases that includes infections, inflammatory conditions, metabolic disease, autoimmunity and neurologic syndromes. The initial discovery of these potentially important correlations has led many laboratories around the world to probe the molecular mechanisms that form the causal link between specific commensal microbes and disease development, progression and resolution. Although there have been great advances, culturing many of the prevalent and metabolically active obligate anaerobic commensals remains a challenge. Exciting advances, however, are emerging from laboratories developing tools to genetically manipulate key commensal organisms, facilitating experimental studies that are identifying the small, bioactive molecules they produce, some of which have therapeutic potential. Studies of the impact of bacteriophage on the microbiota also suggest that they may have therapeutic potential. This Keystone conference will focus on recent advances that demonstrate, at the cellular and molecular level, the impact of the microbiota and its products on disease susceptibility/resistance, with an emphasis on microbial and host metabolism, inter-microbial interactions and the amelioration of diseases.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Innovative Medicines Initiative (IMI) ENABLE Annual Meeting
2021-01-21 | VIRTUAL EVENT
Antimicrobial resistance (AMR) is a major public health threat. Infections caused by resistant bacteria are increasing and causing Europe to face soaring costs both in terms of lives and public health expenditure. Despite the strong need for new antimicrobials, very few new, effective antibiotics have been brought to the market in the last decades. The ENABLE project, within IMI’s New Drugs for Bad Bugs (ND4BB) programme, is working to advance the development of potential antibiotics against Gram-negative bacteria, such as Escherichia coli. The ultimate goal of the project is to develop attractive antimicrobial candidates for testing in the clinic, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients.
CARB-X participants include Erin Duffy, Chief of R&D.
Click here to learn more.

4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference
2021-01-26 - 2021-01-28 | VIRTUAL EVENT
Please make plans to join us for this outstanding line-up of internationally-renowned experts in antimicrobial resistance and stewardship.
Click here to learn more.
Click here to view the agenda.
Click here to register.

5th Microbiome Movement - Drug Development Summit Europe 2021
2021-01-27 - 2021-01-29
Participants include CARB-X funded companies Eligo Bioscience and Seres Therapeutics.
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.
Part of the foremost conference series for microbiome researchers in industry, the 5th Microbiome Movement – Drug Development Europe 2021 will return to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.
To learn more, click here.
To view the program, click here.
To register, click here.

BSAC/GARDP Antimicrobial Chemotherapy Virtual Conference 2021
2021-02-02 - 2021-02-03 | VIRTUAL EVENT
Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators are the Helmholtz Institute for Pharmaceutical Sciences (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)
Click here to learn more.
Click here to register.

C-CAMP AMR Webinar Series: Pre-Clinical and Early Drug Development in India
2021-02-02 10:00 - 12:00 (America/New_York) | VIRTUAL EVENT
India is fast emerging as one of the global hubs for conducting pre- clinical and clinical development. The webinar will showcase the competencies of some of the CROs
in India and how Product Developers can leverage the advantages of working with Indian CROs.
Participating CROs include:

Bioneeds India
Syngene International
SIRO Clinpharm
Sai Life Sciences
GVK Bio

Click here to learn more and register.
Click here to view the zoom link.

The Bloomsbury SET Conference on Infectious Disease and AMR
2021-02-22 - 2021-02-26 | VIRTUAL EVENT
The Bloomsbury SET is hosting its first virtual conference focused on knowledge exchange and infectious disease during the 22nd to 26th February 2021.
Throughout the week, the Bloomsbury SET and wider partners will explore interdisciplinary innovation, research translation, commercialisation, impact and connecting capabilities to tackle global health challenges through knowledge exchange.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Phage Futures Congress
2021-02-24 - 2021-02-26 | VIRTUAL EVENT
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond. Discover how you can be at the forefront of the developing phage therapy market. Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies.
Among other topics, expect to hear & participate in:

Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.
Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.
Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.
Expert advice on how to find & secure financial investments.

CARB-X participants include Richard Alm, Alliance Director.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Live Webinar: GARDP/REVIVE – From discovery to IND: Roadmap to a successful antibacterial project
2021-02-25 11:00 - 12:30 (America/New_York)
Speakers: Patricia Bradford, Antimicrobial Development Specialists LLC (US); Alita Miller, Entasis Therapeutics (US)
Moderator: Michael Mourez, École d’Ingénieurs de PURPAN (France)
The presentations will be followed by a Q&A session.
Click here to learn more and register.

Live Webinar: GARDP/REVIVE – Learning from COVID-19 to tackle the silent pandemic of antibiotic resistance
2021-03-04 10:00 - 11:30 (America/New_York) | VIRTUAL EVENT
The COVID-19 pandemic has brought into sharp focus the impact of pandemics. The novel coronavirus has claimed more than a million lives, trillions of dollars have been lost, expenditures cut and international efforts to achieve the Sustainable Development Goals put in jeopardy.
COVID-19 has demonstrated pandemic preparedness requires a global coordinated effort, and no country can do it alone. Strengthening our ability to fight the silent pandemic of drug-resistant infections must also ensure affordable access to vital health tools, including new and improved treatments. This webinar will focus on how we can apply the lessons learned from COVID-19 to tackle drug resistance and ensure access to appropriate antibiotics.
Speakers:

Manica Balasegaram, GARDP
Joanne Liu, University of Montreal and Médecins Sans Frontières
Marc Mendelson, Groote Schuur Hospital, University of Cape Town

Moderator: Claire Doole
The presentations will be followed by a Q&A session.
Click here to learn more and register.

BARDA AMR Vaccine Public Workshop: Vaccines against AMR Threats
2021-03-12 11:00 - 13:00 (America/New_York) | VIRTUAL EVENT
Multi-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis. Every year, 2.8 million American develop a drug resistant infection and 35,000 people die. Globally, MDR infections kill 700,000 each year – current estimates are that MDR organisms will kill more than 10 million a year by 2050 if left unchecked.
BARDA supports development and procurement of medical countermeasures to protect Americans against chemical, biological, radiological, and nuclear (CBRN) threats. MDR does not discriminate, and victims of CBRN events are at risk of suffering fatal complications from drug resistant infections. One of BARDA’s top priorities is to develop a vaccine to protect people from these threats.
Help BARDA fight AMR! Join the workshop to learn more about BARDA, our mission, and how we plan to tackle this growing threat. The event will consist of presentations from BARDA experts, followed by a structured discussion, and Q&A. Companies and others interested in working with BARDA are encouraged to attend the March 12, 2021 workshop. The event is open to the public, but space is limited. Be sure to register by March 5, 2021. Please, no more than four people from one organization. Are you a product developer working on a vaccine against one of the four targeted pathogens? Then we want to talk with you! Be sure to request a private meeting when you register for the workshop.
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more.
Click here to register.

3rd Bacteriophage Therapy Summit 2021
2021-03-23 - 2021-03-24 | VIRTUAL EVENT
The 3rd Bacteriophage Therapy Summit returns! With a new looking speaker line-up and never before seen content, we are excited to continue to unite the community to progress fundamental bacteriophage research into clinically-significant products.
The overuse of antibiotics had led to the development of multi-resistant bacterial strains, most notably ESKAPE pathogens, rendering the use of antibiotics, which in many scenarios are useless. However, bacteriophages may hold the key in overcoming the global antibiotic resistance crisis.
Although the potential use of phage and phage-derived products in a clinical setting is beginning to be understood, there still remains a number of unique challenges associated with this novel therapeutic agent. A developing regulatory landscape, up-scaling of manufacturing processes, and the design of clinical trials are just a few of the roadblocks holding back development.
Bringing together leading drug developers, academics and clinical researchers, our agenda is focused to address the main translation challenges from characterization of phages through to clinical development. This is your opportunity to join your peers to strengthen your product development pipelines and forge new collaborations to unlock the full potential of bacteriophage therapeutics.
CARB-X participants include Richard Alm, Alliance Director.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Australasian Society for Infectious Diseases (ASID) Annual Scientific Meeting
2021-03-24 - 2021-03-26 | Pullman Melbourne on the Park, 192 Wellington Parade, MELBOURNE, 3002, Australia
The ASID Annual Scientific Meeting is the leading Australasian meeting for adult and paediatric infectious disease and clinical microbiology specialists. The conference is an ideal opportunity for connecting clinicians, microbiologists and other health professions with a common interest in infectious diseases and provides a friendly forum for the exchange of scientific advances in the prevention, diagnosis and management of clinical infectious diseases. International speakers will offer expert global perspectives on our themes and Australasian research and expertise will be highlighted with keynote lectures, proffered papers and symposia. The main theme is “Hospital Infectious Diseases”
Click here to learn more.
Click here to view the agenda.
Click here to register.

The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (Levy CIMAR) Monthly Science Meeting: Innovation Solutions to AMR
2021-03-25 12:00 - 13:00 (America/New_York) | VIRTUAL EVENT
Please join us on Thursday, March 25th, at noon for this month’s Levy CIMAR Science Meeting on “Innovation Solutions to AMR.” We are excited to hear from Kevin Outterson, Esq., Professor of Law at Boston University and Executive Director of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X. CARB-X is a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections.
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more about Levy CIMAR.
Contact Rima Mycynek @ Rima.Mycynek@tufts.edu for Zoom Details.

Decennial Day: 6th International Conference on Healthcare Associated Infections
2021-04-12
We are excited to announce ‘Decennial Day’ which will be a complimentary program to SHEA Spring 2021. Decennial Day will feature a few selected sessions from the 2020 Decennial Program to be virtually held on April 12, 2021. More information to come on sessions and speakers at a later date.
You will automatically be registered for Decennial Day when you register for SHEA Spring 2021. If you wish to only sign up for Decennial Day (and not SHEA Spring) you may do so. Learn More
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more.
Click here to view the agenda.
Click here to register.

SHEA Spring 2021 Conference
2021-04-13 - 2021-04-16 | VIRTUAL EVENT
Who should come to SHEA Spring 2021?
SHEA members and non-members of all disciplines relating to Infection Prevention Programs, Antibiotic Stewardship Programs, Public Health, Pharmacy, Occupational Health, Clinical Microbiology, Quality Improvement, and Patient Safety. If you are involved in infection prevention or infection control you need to be at SHEA Spring 2021!
Click here to learn more.
Click here to view the agenda.
Click here to register.

Anti-Infectives Drug Development Summit
2021-04-20 - 2021-04-22 | VIRTUAL EVENT
Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
CARB-X participants include Kevin Outterson, Executive Director, who will be leading the session “Surviving FDA Approval of your Antibiotic” on Wednesday April 21 at 9:25am ET / 6:25am PDT. He will touch upon:

What can we learn from the past decade of FDA antibiotic approvals? •
Niche markets where your drug can differentiate from generics
Non-dilutive funding: CARB-X, BARDA, HERA
Exit: AMR Action Fund, PASTEUR

CARB-X funded companies participating include Peptilogics, Vedanta, Antabio, Bioversys, ContraFect, Locus, Techulon, Summit, and MicuRx.
Click here to learn more.
Click here to view the event guide.
Click here to register.

JPIAMR Therapeutics Workshop - Feeding the Antimicrobial Pipeline
2021-04-20 - 2021-04-22
As AMR emerges, new strategies for the treatment of infection and identification of resistant microbes are crucial. This JPIAMR activity, led by the UK Medical Research Council (MRC) with support from South Africa (SAMRC), Korea (NRF), France (ANR), and Canada (CIHR) is delivered as part of JPIAMR’s mission to enable global coordination of research.
The workshop “Feeding the AMR Therapeutics Pipeline” will bring together academics, industry, innovators, and policymakers to discuss the global antimicrobial development pipeline, identify gaps and opportunities for future research and development, and support collaboration for creative solutions to real-world problems facing therapeutics development in the context of antimicrobial resistance (AMR).
The workshop is organised online in three half-day sessions, (13:00-17:00 CET) from the 20th to the 22nd of April 2021, combining keynote presentations, short invited talks selected from abstract submissions, and panel discussions.
CARB-X participants include Kevin Outterson, Executive Director, who will be leading session “Session 2 Choosing wisely – is your product worth developing?” which will take place between 14:50 to 15:50 CET on April 20th.
Click here to learn more.
Click here to register.

Anti-Infectives Drug Development Summit
2021-04-20 - 2021-04-22 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
Here is a sneak peak of the world-class speaker faculty:

Cara Cassino, Executive Vice President of R&D & Chief Medical Officer, ContraFect
Kevin Outterson, Executive Director, CARB-X
Silas Holland, Head of External Affairs (Interim) & Director of Global Policy, Merck & The AMR Action Fund
David Powell, Chief Scientific Officer, Summit Therapeutics
Dave Ousterout, Chief Scientific Officer, Locus Biosciences
Angela Talley, Vice President of Clinical Development, Spero Therapeutics
Ercem Atillasoy, Chief Regulatory & Safety Officer, AlloVir
David Alterac, Chief Medical Officer, Entasis Therapeutics

Click here to learn more.
Click here to view the agenda.
Click here to register.

Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea; Public Workshop
2021-04-23 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
FDA, NIAID and CDC are announcing a public workshop regarding the development considerations of antimicrobial drugs for the treatment of gonorrhea. The workshop will focus on the current state and nonclinical and clinical trial design considerations regarding antimicrobial drug development for gonorrhea and include the following topic areas:

Animal models
Clinical pharmacology considerations
Trial design considerations for gonorrhea, such as enrollment strategies, choice of comparators and site of infection.

This meeting will be held in virtual format only. Registration is required for online attendance.
To learn more, click here.
Additional details forthcoming.

9th Annual Cystic Fibrosis Symposium 2021
2021-04-24 08:00 - 12:30 (America/Los_Angeles) | Auditorium at UCLA Medical Center, Santa Monica, 1250 16th Street, Santa Monica, CA, 90404, United States
This course is designed to increase the knowledge of managing patients with CF across the lifespan of all who interact with this population.
About this Event
The target audience includes nurses, respiratory therapists, physical and occupational therapists, social workers, dieticians, child life specialists, and physicians
Click here to learn more and register.

BactiVac Online: Virtual Network Conference 2021
2021-04-27 - 2021-04-28 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Delivering our 2021 Virtual Network Conference in an innovative online format will provide a unique opportunity to hear about the latest bacterial vaccinology research from leading international researchers in a safe environment. Talks will be delivered by a host of internationally renowned speakers from a range of disciplines, all actively involved in the research area of bacterial vaccinology. Please view the programme for our virtual conference, together with speaker profiles.
The conference is open and free to attend for BactiVac Network members only and booking is compulsory; you can apply for free membership here. Registration for the conference is now closed.
Keep up to date by following us on @BactiVac, using #BactiVacEvents. You can also download BactiVac Virtual Conference flyer to circulate and/or display within your organisation.
For any queries regarding virtual conference, please contact us at: bactivac@contacts.bham.ac.uk
Click here to learn more.

BSAC Spring Conference
2021-04-29 - 2021-04-30
Additional details forthcoming. Click here to learn more.
